Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of navarixin plus pembrolizumab in selected advanced or metastatic solid tumors
MOH_2018-03-28_002180Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of navarixin and pembrolizumab in non-small cell lung cancer (NSCLC), prostate cancer (PCa), colorectal cancer (CRC) and 1 more (2 arms), sponsored by Merck & Co. Started Mar 2018; status: completed.
02
Drugs
navarixinpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)prostate cancer (PCa)colorectal cancer (CRC)Nonhematologic neoplasms
Beyond the preview
Go deeper on MOH_2018-03-28_002180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-03-28_002180.